Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo

Study Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Program Consisting of a Phase 2b Trial and a Phase 3 Trial to Evaluate the Efficacy and Safety of TEV-53408 in Participants With Non-Segmental Vitiligo
Teva Identifier
TV53408-IMM-30105
ClinicalTrials.gov Identifier
NCT07920211
Study Status
Not yet recruiting
Trial Condition(s)
Vitiligo
Interventions
Drug: TEV-53408|Drug: Placebo
EU CT Number
2026-527760-32-00
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
allergy-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years and older
Trial Duration
November 16, 2026 - June 19, 2031
Phase
Phase 2/3

Study Type

Interventional